A comparison of calcium pentagastrin and TRH tests in screening for medullary carcinoma of the thyroid in MEN IIA.
Intravenous injections of calcium gluconate and pentagastrin (CPG) or TRH were compared as secretagogues for calcitonin (CT) in screening for medullary thyroid carcinoma (MTC) in multiple endocrine neoplasia type IIA (MEN IIA). Administration of CPG resulted in a prompt increase in plasma CT in all five patients with MTC studied, one of whom had a normal baseline value (peak 412-371,000 ng/l, 636-4847% above basal). TRH produced a rise in plasma CT levels only in MTC patients with elevated basal values; the magnitude of increase was less than that observed with CPG (peak 168-17,200 ng/l, 113-180% above basal). CT levels did not rise above 300 ng/l with either test in four unaffected first-degree relatives of MEN IIA patients, three subjects with sporadic unilateral phaeochromocytomas and five controls with essential hypertension. CPG remains the CT secretagogue of choice in screening for MTC in MEN II A.
O'Connell
J E
JE
MRC Blood Pressure Unit, Western Infirmary, Glasgow, UK.
Dominiczak
A F
AF
Isles
C G
CG
McLellan
A R
AR
Davidson
G
G
Gray
C E
CE
Connell
J M
JM
D000328:Adult; D002116:Calcitonin / Q000097:blood; D002125:Calcium Gluconate; D002277:Carcinoma / Q000097:blood / Q000175:diagnosis*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009377:Multiple Endocrine Neoplasia / Q000097:blood / Q000175:diagnosis*; D010418:Pentagastrin; D013268:Stimulation, Chemical; D013964:Thyroid Neoplasms / Q000097:blood / Q000175:diagnosis*; D013973:Thyrotropin-Releasing Hormone
D013973:Thyrotropin-Releasing Hormone; D002116:Calcitonin; D010418:Pentagastrin; D002125:Calcium Gluconate